200 related articles for article (PubMed ID: 32393322)
21. Screening and identification of potential biomarkers and therapeutic targets for systemic sclerosis-associated interstitial lung disease.
Huang B; Li J; Zhao J
Arch Rheumatol; 2021 Dec; 36(4):548-559. PubMed ID: 35382367
[TBL] [Abstract][Full Text] [Related]
22. Predictive role of circulatory HMGB1 in postoperative acute exacerbation of interstitial lung disease in lung cancer patients.
Yamaguchi K; Nakao S; Iwamoto H; Kagimoto A; Handa Y; Sakamoto S; Horimasu Y; Masuda T; Mimae T; Miyamoto S; Nakashima T; Tsutani Y; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
Sci Rep; 2021 May; 11(1):10105. PubMed ID: 33980944
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity.
Yoshizaki A; Komura K; Iwata Y; Ogawa F; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
J Clin Immunol; 2009 Mar; 29(2):180-9. PubMed ID: 18825489
[TBL] [Abstract][Full Text] [Related]
24. Serum cold-inducible RNA-binding protein levels as a potential biomarker for systemic sclerosis-associated interstitial lung disease.
Omori I; Sumida H; Sugimori A; Sakakibara M; Urano-Takaoka M; Iwasawa O; Saito H; Matsuno A; Sato S
Sci Rep; 2023 Mar; 13(1):5017. PubMed ID: 36977758
[TBL] [Abstract][Full Text] [Related]
25. Decreased sputum caveolin-1 is associated with systemic sclerosis related lung disease.
Yilmaz N; Olgun S; Ahiskali R; Karakurt S; Yavuz S
Sarcoidosis Vasc Diffuse Lung Dis; 2014 Apr; 31(1):55-61. PubMed ID: 24751454
[TBL] [Abstract][Full Text] [Related]
26. Serum high-mobility group box 1 as a predictive marker for cytotoxic chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease.
Nakao S; Yamaguchi K; Iwamoto H; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Ohshimo S; Fujitaka K; Hamada H; Hattori N
Respir Med; 2020 Oct; 172():106131. PubMed ID: 32911136
[TBL] [Abstract][Full Text] [Related]
27. Proteomic aptamer analysis reveals serum biomarkers associated with disease mechanisms and phenotypes of systemic sclerosis.
Motta F; Tonutti A; Isailovic N; Ceribelli A; Costanzo G; Rodolfi S; Selmi C; De Santis M
Front Immunol; 2023; 14():1246777. PubMed ID: 37753072
[TBL] [Abstract][Full Text] [Related]
28. Serum concentration of surfactant protein D in patients with systemic sclerosis: The potential marker of the interstitial lung disease severity.
Grosicka A; Manasar A; Kucharz EJ; Kotyla PJ
Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):541-549. PubMed ID: 31174823
[TBL] [Abstract][Full Text] [Related]
29. Red blood cell distribution width as a related factor of pulmonary arterial hypertension in patients with systemic sclerosis.
Zhao J; Mo H; Guo X; Wang Q; Xu D; Hou Y; Tian Z; Liu Y; Wang H; Lai J; Li M; Zeng X
Clin Rheumatol; 2018 Apr; 37(4):979-985. PubMed ID: 29164429
[TBL] [Abstract][Full Text] [Related]
30. Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease.
Martyanov V; Kim GJ; Hayes W; Du S; Ganguly BJ; Sy O; Lee SK; Bogatkevich GS; Schieven GL; Schiopu E; Marangoni RG; Goldin J; Whitfield ML; Varga J
PLoS One; 2017; 12(11):e0187580. PubMed ID: 29121645
[TBL] [Abstract][Full Text] [Related]
31. Ability of the COPD Assessment Test to evaluate the lung-specific quality of life in systemic sclerosis-associated interstitial lung disease.
Mugii N; Someya F
Clin Respir J; 2020 Jun; 14(6):527-532. PubMed ID: 32045097
[TBL] [Abstract][Full Text] [Related]
32. Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort.
Hoffmann-Vold AM; Fretheim H; Halse AK; Seip M; Bitter H; Wallenius M; Garen T; Salberg A; Brunborg C; Midtvedt Ø; Lund MB; Aaløkken TM; Molberg Ø
Am J Respir Crit Care Med; 2019 Nov; 200(10):1258-1266. PubMed ID: 31310156
[No Abstract] [Full Text] [Related]
33. Decreased serum cathepsin S levels in patients with systemic sclerosis-associated interstitial lung disease.
Toyama S; Yamashita T; Saigusa R; Miura S; Nakamura K; Hirabayashi M; Miyagawa T; Fukui Y; Omatsu J; Yoshizaki A; Sato S; Asano Y
J Dermatol; 2020 Sep; 47(9):1027-1032. PubMed ID: 32515028
[TBL] [Abstract][Full Text] [Related]
34. Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease.
Valenzi E; Bulik M; Tabib T; Morse C; Sembrat J; Trejo Bittar H; Rojas M; Lafyatis R
Ann Rheum Dis; 2019 Oct; 78(10):1379-1387. PubMed ID: 31405848
[TBL] [Abstract][Full Text] [Related]
35. Dynamics of serum angiopoietin-2 levels correlate with efficacy of intravenous pulse cyclophosphamide therapy for interstitial lung disease associated with systemic sclerosis.
Takahashi T; Asano Y; Akamata K; Aozasa N; Taniguchi T; Noda S; Masui Y; Ichimura Y; Toyama T; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
Mod Rheumatol; 2013 Sep; 23(5):884-90. PubMed ID: 22972016
[TBL] [Abstract][Full Text] [Related]
36. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
[TBL] [Abstract][Full Text] [Related]
37. [Increase of CXCL10 serum level in systemic sclerosis interstitial pneumonia].
Tiev KP; Chatenoud L; Kettaneh A; Tolédano C; Bach JF; Cabane J
Rev Med Interne; 2009 Nov; 30(11):942-6. PubMed ID: 19577826
[TBL] [Abstract][Full Text] [Related]
38. Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort.
Noviani M; Saffari SE; Tan JL; Yip JWL; Teng GG; Law WG; Chan GYL; Santosa A; Lim AYN; Hong C; Ng SA; Tay ELW; Ruan W; Yap J; Low AHL
Semin Arthritis Rheum; 2020 Jun; 50(3):473-479. PubMed ID: 31810742
[TBL] [Abstract][Full Text] [Related]
39. HMGB1 May Be a Biomarker for Predicting the Outcome in Patients with Polymyositis /Dermatomyositis with Interstitial Lung Disease.
Shu X; Peng Q; Lu X; Wang G
PLoS One; 2016; 11(8):e0161436. PubMed ID: 27537498
[TBL] [Abstract][Full Text] [Related]
40. Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis.
Andersen GN; Nilsson K; Pourazar J; Hackett TL; Kazzam E; Blomberg A; Waldenström A; Warner J; Rantapää-Dahlqvist S; Mincheva-Nilsson L; Sandström T
Respir Med; 2007 Oct; 101(10):2199-206. PubMed ID: 17643278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
